ZM306416 ZM-306416 CAS:690206-97-4

CAS NO: 690206-97-4
ZM306416 CAS:690206-97-4
Chemical Name: 4-[(4-Bromophenyl)amino]-6,7-dimethoxyquinazoline
Molecular Formula: C_17H_15BrN_4O_2
Formula Weight: 385.23 g/mol
CAS Number: 690206-97-4
Description Review
Description
The compound ZM306416, CAS number 690206-97-4, is a novel advance in the field of oncology. Specifically, it is designed to suppress angiogenesis, a critical mechanism involved in the development and spread of tumors. This chemical has received interest due to its possible significance in altering crucial cancer growth pathways.



Trending Search on Google
"ZM306416 inhibiting VEGFR."
"ZM-306416 cancer treatment",
"The compound with CAS number 690206-97-4 has been found to have an effect on angiogenesis."
"ZM306416 clinical trials,"
"ZM-306416 pharmacology",
"ZM306416 tumor suppression,"
"ZM-306416 drug profile"
"ZM306416 for therapeutic applications,"
"ZM-306416 oncology research,"
"Understanding the mechanism of action for ZM306416."

Similar Products from Competitors
Similar to Bevacizumab, Sunitinib, and Sorafenib, which are utilized in diverse cancer therapies with the aim of inhibiting angiogenesis, ZM306416 belongs to its therapeutic class of VEGFR inhibitors.

Advantages for Well-being
Inhibiting angiogenesis—the process by which cancers, especially solid tumors, get blood to fuel their development and metastasis—may be ZM306416's principal health effect.


Possible Consequences
It is possible that ZM306416 might have a major influence on the growth of tumors by blocking VEGFR, which plays an important role in the production of new blood vessels. It may limit tumor development and metastatic potential.


Product Operation
ZM306416 inhibits VEGFR tyrosine kinase activity selectively. It inhibits the downstream signaling pathways accountable for angiogenesis by binding to this receptor and preventing the phosphorylation and subsequent activation of VEGFR.

Side Effects and Safety
Clinical studies are now being conducted to assess the safety and side effect profile of ZM306416, an investigational treatment. In addition to hypertension, tiredness, and gastrointestinal problems, potential adverse effects may be similar to those that are associated with other VEGFR inhibitors.


Information on Dosing
Clinical studies with a focus on safety and effectiveness are being used to identify the ideal dosage schedule for ZM306416.

Important Considerations
Initial contraindications for ZM306416 would most likely include allergy to the medicine or its components. Owing to the drug's potential interactions with other medications and particular patient conditions, additional contraindications may be discerned.


In summary
As an anti-angiogenic therapeutic drug, ZM306416 (ZM-306416) shows promise, particularly in cancer treatment. For cancers that are largely dependent on angiogenesis, the creation of this substance and its possible use in clinical oncology might open up new pathways in the battle against cancer.


Section "People Also Ask"
Which cancer kinds may ZM306416 be successful against?
A: ZM306416 is being studied largely for its effectiveness in solid tumors where angiogenesis is important, such as renal, colorectal, and breast malignancies.

In contrast to other anti-angiogenic medications, what distinguishes ZM306416?
When compared to other medications on the market, ZM306416 may have better effectiveness and fewer adverse effects due to its novel pharmacokinetic features and mode of action.


Are ZM306416's uses approved?
A phase of clinical studies is now underway to determine the safety and effectiveness of ZM306416, since it is not yet licensed for use in clinical settings.

Q: What are the recognized negative effects of ZM306416 in clinical trials?
A: The detailed side effect profiles will become more obvious as clinical studies continue, however they may include symptoms that are often linked with VEGFR inhibitors. These symptoms may include hypertension, tiredness, and gastrointestinal problems.


  • "ZM306416 VEGFR inhibitor",
  • "ZM-306416 cancer therapy",
  • "ZM306416 angiogenesis inhibition",
  • "ZM-306416 clinical trials",
  • "ZM306416 pharmacodynamics",
  • "ZM-306416 therapeutic potential",
  • "ZM306416 molecular mechanism",
  • "ZM-306416 tumor growth inhibition",
  • "ZM306416 drug profile",
  • "ZM-306416 in oncology".
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code